InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Friday. The firm issued a sell rating on the stock.

Several other brokerages have also recently commented on NSPR. Lake Street Capital started coverage on InspireMD in a research report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price for the company. Piper Sandler reissued an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Trading Up 0.7 %

NYSE NSPR opened at $3.00 on Friday. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.42. The company has a market cap of $78.25 million, a PE ratio of -4.00 and a beta of 0.98. The stock’s 50-day moving average price is $2.69 and its two-hundred day moving average price is $2.69.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The business had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. During the same quarter in the previous year, the business earned ($0.15) earnings per share. Research analysts forecast that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC acquired a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent quarter. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.